General practitioners' deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries.
Deprescribing
Multimorbidity
Old age
Polypharmacy
Primary health care
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
06
04
2020
accepted:
09
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
24
4
2021
Statut:
epublish
Résumé
General practitioners (GPs) should regularly review patients' medications and, if necessary, deprescribe, as inappropriate polypharmacy may harm patients' health. However, deprescribing can be challenging for physicians. This study investigates GPs' deprescribing decisions in 31 countries. In this case vignette study, GPs were invited to participate in an online survey containing three clinical cases of oldest-old multimorbid patients with potentially inappropriate polypharmacy. Patients differed in terms of dependency in activities of daily living (ADL) and were presented with and without history of cardiovascular disease (CVD). For each case, we asked GPs if they would deprescribe in their usual practice. We calculated proportions of GPs who reported they would deprescribe and performed a multilevel logistic regression to examine the association between history of CVD and level of dependency on GPs' deprescribing decisions. Of 3,175 invited GPs, 54% responded (N = 1,706). The mean age was 50 years and 60% of respondents were female. Despite differences across GP characteristics, such as age (with older GPs being more likely to take deprescribing decisions), and across countries, overall more than 80% of GPs reported they would deprescribe the dosage of at least one medication in oldest-old patients (> 80 years) with polypharmacy irrespective of history of CVD. The odds of deprescribing was higher in patients with a higher level of dependency in ADL (OR =1.5, 95%CI 1.25 to 1.80) and absence of CVD (OR =3.04, 95%CI 2.58 to 3.57). The majority of GPs in this study were willing to deprescribe one or more medications in oldest-old multimorbid patients with polypharmacy. Willingness was higher in patients with increased dependency in ADL and lower in patients with CVD.
Sections du résumé
BACKGROUND
General practitioners (GPs) should regularly review patients' medications and, if necessary, deprescribe, as inappropriate polypharmacy may harm patients' health. However, deprescribing can be challenging for physicians. This study investigates GPs' deprescribing decisions in 31 countries.
METHODS
In this case vignette study, GPs were invited to participate in an online survey containing three clinical cases of oldest-old multimorbid patients with potentially inappropriate polypharmacy. Patients differed in terms of dependency in activities of daily living (ADL) and were presented with and without history of cardiovascular disease (CVD). For each case, we asked GPs if they would deprescribe in their usual practice. We calculated proportions of GPs who reported they would deprescribe and performed a multilevel logistic regression to examine the association between history of CVD and level of dependency on GPs' deprescribing decisions.
RESULTS
Of 3,175 invited GPs, 54% responded (N = 1,706). The mean age was 50 years and 60% of respondents were female. Despite differences across GP characteristics, such as age (with older GPs being more likely to take deprescribing decisions), and across countries, overall more than 80% of GPs reported they would deprescribe the dosage of at least one medication in oldest-old patients (> 80 years) with polypharmacy irrespective of history of CVD. The odds of deprescribing was higher in patients with a higher level of dependency in ADL (OR =1.5, 95%CI 1.25 to 1.80) and absence of CVD (OR =3.04, 95%CI 2.58 to 3.57).
INTERPRETATION
The majority of GPs in this study were willing to deprescribe one or more medications in oldest-old multimorbid patients with polypharmacy. Willingness was higher in patients with increased dependency in ADL and lower in patients with CVD.
Identifiants
pubmed: 33413142
doi: 10.1186/s12877-020-01953-6
pii: 10.1186/s12877-020-01953-6
pmc: PMC7792080
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 407440_167465
Organisme : National Institute for Health Research (NIHR) Applied Research Collaborations (West Midlands), the NIHR School for Primary Care Research and an NIHR Research Professorship in General Practice
ID : RP 2014-04-026
Références
BMJ. 1996 Sep 21;313(7059):732-3; discussion 733-4
pubmed: 8819446
Med Care. 2016 Oct;54(10):950-64
pubmed: 27367864
BMC Fam Pract. 2018 Oct 12;19(1):169
pubmed: 30314468
Eur J Hosp Pharm. 2017 Jan;24(1):43-46
pubmed: 31156897
Arch Intern Med. 2011 Jun 13;171(11):1013-9
pubmed: 21670370
J Patient Saf. 2009 Jun;5(2):61-6
pubmed: 19920442
Eur J Clin Pharmacol. 2017 May;73(5):601-608
pubmed: 28093640
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):651-668
pubmed: 28460576
J Am Geriatr Soc. 2020 Jan;68(1):78-86
pubmed: 31509233
J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):423-9
pubmed: 24293516
Br J Gen Pract. 2016 Aug;66(649):e552-60
pubmed: 27266865
Ann Fam Med. 2017 Jul;15(4):341-346
pubmed: 28694270
Ann Pharmacother. 2005 Mar;39(3):412-7
pubmed: 15687479
CMAJ. 2017 May 15;189(19):E706-E707
pubmed: 28507095
J Am Coll Cardiol. 2019 May 28;73(20):2584-2595
pubmed: 31118153
J Am Geriatr Soc. 2009 Jun;57(6):1007-14
pubmed: 19467144
BMC Geriatr. 2017 Apr 20;17(1):93
pubmed: 28427345
Can Fam Physician. 2017 May;63(5):354-364
pubmed: 28500192
N Engl J Med. 2018 Oct 18;379(16):1519-1528
pubmed: 30221595
Am J Geriatr Pharmacother. 2006 Mar;4(1):36-41
pubmed: 16730619
N Engl J Med. 2018 Oct 18;379(16):1529-1539
pubmed: 30146931
J Am Geriatr Soc. 2019 Jan;67(1):172-180
pubmed: 30315745
J Eval Clin Pract. 2010 Feb;16(1):69-75
pubmed: 20367817
Med J Aust. 2019 Mar;210(4):174-179
pubmed: 30771226
BMJ Open. 2014 Dec 08;4(12):e006544
pubmed: 25488097
Pharmacoepidemiol Drug Saf. 2011 May;20(5):514-22
pubmed: 21308855
Aust Fam Physician. 2012 Dec;41(12):924-8
pubmed: 23210113
J Med Internet Res. 2004 Sep 29;6(3):e34
pubmed: 15471760
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Qual Health Res. 2017 Nov;27(13):1936-1947
pubmed: 29088989
BMC Geriatr. 2019 May 29;19(1):154
pubmed: 31142286
BJGP Open. 2018 Apr 10;2(1):bjgpopen18X101325
pubmed: 30564700
J Gen Intern Med. 2019 Sep;34(9):1751-1757
pubmed: 30652277
Br J Clin Pharmacol. 2015 Dec;80(6):1254-68
pubmed: 27006985
BMC Fam Pract. 2016 Nov 5;17(1):152
pubmed: 27814691
JAMA Intern Med. 2015 May;175(5):827-34
pubmed: 25798731
Age Ageing. 2015 Jul;44(4):704-8
pubmed: 25758409
Ann Pharmacother. 2016 Jun;50(6):446-54
pubmed: 26939589
Geriatr Gerontol Int. 2018 Jul;18(7):1064-1070
pubmed: 29582533
Clin Epidemiol. 2018 Mar 12;10:289-298
pubmed: 29559811
Clin Ther. 2006 Aug;28(8):1133-1143
pubmed: 16982290
Can Fam Physician. 2017 Nov;63(11):832-843
pubmed: 29138153
Br J Gen Pract. 2015 Mar;65(632):e184-91
pubmed: 25733440
Can Fam Physician. 2018 May;64(5):339-351
pubmed: 29760253
CMAJ. 2018 Sep 24;190(38):E1134-E1140
pubmed: 30249759
Lancet. 2018 Sep 22;392(10152):1036-1046
pubmed: 30158069
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
Ther Clin Risk Manag. 2018 Sep 04;14:1591-1597
pubmed: 30233194
CMAJ. 2014 Apr 1;186(6):407-8
pubmed: 24638028
Drugs Aging. 2013 Oct;30(10):793-807
pubmed: 23912674
Med J Aust. 2014 Oct 6;201(7):386-9
pubmed: 25296058
Am J Geriatr Pharmacother. 2010 Jun;8(3):215-24
pubmed: 20624611
Can Fam Physician. 2018 Jan;64(1):17-27
pubmed: 29358245